May 2025 - BioMedWire (BMW)

FridayMay 30, 2025 10:00 am

Study Links Autism to Increased Risk of Developing Parkinson’s Disease

A recently conducted study by a team at Karolinska Institutet in Sweden has established a link between a diagnosis of autism spectrum disorder (ASD) to a heightened risk of Parkinson’s disease (PD). The research appeared in the journal JAMA Neurology. The research team believes the two conditions may share a number of underlying biological mechanisms. The team based their study on data on more than two million individuals born in Sweden in the years 1974-1999. The registry data tracked these individuals starting at age 20 and the researchers analyzed this data covering those years until 2022. The team was interested…

ThursdayMay 29, 2025 10:20 am

Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs

Alzamend Neuro tackles Alzheimer’s, BD, MDD and PTSD with breakthrough therapies. AL001 delivers improved brain targeting and fewer side effects than lithium carbonate. Phase II trials underway with support from Mass General and AI partner QMENTA. ALZN002 offers a novel, adjuvant-free immunotherapy for Alzheimer’s disease. Alzamend Neuro (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company tackling some of the most pressing neurological and psychiatric conditions of our time — including Alzheimer’s disease, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). With a mission to “Make Alzheimer’s Just a Memory™,” the Atlanta-based company is advancing a robust pipeline…

ThursdayMay 29, 2025 10:00 am

University of Houston Gets $3M to Establish Biomarker Core for Cancer Immunotherapy

Texas’ Cancer Prevention & Research Institute has awarded $3 million to the University of Houston to establish a biomarker core for cancer immunotherapy. The research institute has earned a reputation for funding research projects which are groundbreaking. The $3m is a fraction of its $93m total package earmarked for awarding grants to entities within the state. The biomarker core to be established is planned to be a cutting-edge facility in the state geared at availing researchers comprehensive biomarker screens for conducting proteomic cancer research, especially in the fields of cancer immunotherapy and cancer biology. The new facility will be the…

WednesdayMay 28, 2025 10:00 am

House Approves Reconciliation Bill, Health Insurance and Medicaid to Be Impacted

On May 22, the U.S. House of Representatives approved the reconciliation bill for the 2025 budget with a one-vote difference between those in support of the bill and those opposed to it. The American Hospital Association says this legislation is going to have notable impacts upon healthcare insurance and Medicaid. Rick Pollack, the CEO and President of AHA, wrote to Congress on the eve of the House vote. In that statement, he expressed the association’s concerns about several provisions focused on the health insurance marketplace and Medicaid. He pointed out that the reductions to Medicaid funding are likely to have…

WednesdayMay 28, 2025 9:45 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined with a prior strategic investment, for which a financing term sheet has also been signed, the total financing investment, assuming both are closed, represents an expected $10.3 million for HOPE acquisition funding, supporting initial acquisitions of Dura Medical, Kadima, and NeuroSpa clinics. The expanding HOPE clinic network will deliver neuroplastic therapies for depression and PTSD, including ketamine and TMS. NRx continues regulatory progress for NRX-100 (IV ketamine) and NRX-101 (oral bipolar depression therapy). The FDA waived NRx’s $4.3 million drug application fee, and patents could…

TuesdayMay 27, 2025 10:00 am

New Swallowable Pill Provides Real-Time Gut Inflammation Tracking

The GI tract and its components like the mucosal lining play an important role of preventing harmful substances from finding their way into the bloodstream. When this mucosal lining is compromised, serious consequences like the entry of undigested food, toxins and bacteria into the bloodstream result. “Leaky gut” is responsible for conditions like inflammatory bowel disease. Existing tools for monitoring the mucus lining in the gut have limitations, such as being invasive and not providing continuous tracking. Approaches like endoscopy also don’t provide data on the entire GI tract and the updates they provide don’t come in real time. There…

FridayMay 23, 2025 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics

The overuse and misuse of antibiotics have led to the emergence of antibiotic-resistant bacteria, posing a significant threat to public health. Soligenix’s SGX943 is a novel broad-spectrum therapy designed to treat bacterial infections without relying on conventional antibiotics. Preclinical studies have demonstrated the efficacy of SGX943 in various models of bacterial infection. In the face of escalating antibiotic resistance, the medical community is urgently seeking alternative treatments for bacterial infections. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is at the forefront of this effort with its development of SGX943 (dusquetide), a novel broad-spectrum therapy designed to combat bacterial infections without relying…

FridayMay 23, 2025 10:30 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network of psychiatric clinics. The acquisition brings profitability and is expected to be accretive to both revenue and EBITDA. Kadima’s founder and medical director, Dr. David Feifel, a leader in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer. NRx’s pipeline includes investigational drugs for suicidal bipolar depression and chronic pain. HOPE is targeting 30 clinic acquisitions by the end of 2025, projecting $100M in annual revenue. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly owned subsidiary HOPE Therapeutics, Inc., a medical…

FridayMay 23, 2025 9:00 am

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows

Intelligent Bio Solutions remains on track for a 2025 U.S. launch of its non-invasive Intelligent Fingerprinting Drug Screening System. The company’s FDA 510(k) submission included validation studies showing 94.1% accuracy in detecting opiates through fingerprint sweat. INBS is already active in 24 countries, with over 450 commercial accounts globally, and adoption growing across diverse industries, including logistics, mining, retail, and marine operations. The firm is expanding its distributor network to support localized growth ahead of its U.S. market entry. Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is preparing for its expected U.S.…

ThursdayMay 22, 2025 10:30 am

Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization

AVERSA Fentanyl has potential to become the world’s first opioid pain patch with abuse deterrent properties, CEO states in report Nutriband and Kindeva Drug Delivery have formalized a strong product-development partnership and long-term commitment Other key steps outlined as company works to develop, scale-up manufacturing process to bring Aversa technology closer toward commercialization In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan shared significant company achievements and milestones as well as his expectations for 2025 (https://ibn.fm/9K5zT). At the center of the company’s positive outlook for future is noteworthy progress made toward the commercialization of its proprietary Aversa technology, including…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Month: May 2025

Study Links Autism to Increased Risk of Developing Parkinson’s Disease

Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs

University of Houston Gets $3M to Establish Biomarker Core for Cancer Immunotherapy

House Approves Reconciliation Bill, Health Insurance and Medicaid to Be Impacted

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

New Swallowable Pill Provides Real-Time Gut Inflammation Tracking

Soligenix Inc. (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows

Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search